MX339452B - Tableta con nucleo recubierto de liberacion controlada. - Google Patents

Tableta con nucleo recubierto de liberacion controlada.

Info

Publication number
MX339452B
MX339452B MX2012014437A MX2012014437A MX339452B MX 339452 B MX339452 B MX 339452B MX 2012014437 A MX2012014437 A MX 2012014437A MX 2012014437 A MX2012014437 A MX 2012014437A MX 339452 B MX339452 B MX 339452B
Authority
MX
Mexico
Prior art keywords
controlled release
nucleated tablet
isobutyloxyphenyl
cyano
methyl
Prior art date
Application number
MX2012014437A
Other languages
English (en)
Other versions
MX2012014437A (es
Inventor
Kentaro Fujinaga
Susumu Maruo
Hideaki Nakamura
Kenji Sunagawa
Tsutomu Mochizuki
Michiharu Kageyama
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of MX2012014437A publication Critical patent/MX2012014437A/es
Publication of MX339452B publication Critical patent/MX339452B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una tableta de liberación controlada que contiene un núcleo interno y una porción de capa externa que cubre el núcleo interno, la cual puede mantener la concentración de ácido 2-(3-ciano-4-isobutiloxifenil)-4-metil-5-ti azolcarboxílico en la sangre a un cierto nivel o superior durante un largo período de tiempo, donde el núcleo interno contiene ácido 2-(3-ciano-4-isobutiloxifenhl)-4-metil-5-tiazolcarboxílico, y la porción de capa externa contiene ácido 2-(3-ciano-4-isobutilo xifenil)-4-metil-5-tiazol carboxílico y un polímero hidrosoluble formador de gel en una cantidad de 16%. (p/p) o superior con respecto al peso de la porción de capa externa.
MX2012014437A 2010-06-16 2011-06-15 Tableta con nucleo recubierto de liberacion controlada. MX339452B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010137322 2010-06-16
JP2010137323 2010-06-16
PCT/JP2011/063713 WO2011158870A1 (ja) 2010-06-16 2011-06-15 放出制御型の有核錠剤

Publications (2)

Publication Number Publication Date
MX2012014437A MX2012014437A (es) 2013-02-26
MX339452B true MX339452B (es) 2016-05-27

Family

ID=45348267

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012014437A MX339452B (es) 2010-06-16 2011-06-15 Tableta con nucleo recubierto de liberacion controlada.

Country Status (9)

Country Link
US (1) US8968779B2 (es)
EP (1) EP2594269A4 (es)
JP (1) JP5669837B2 (es)
AR (1) AR081935A1 (es)
CA (1) CA2802831C (es)
MX (1) MX339452B (es)
TW (1) TW201206502A (es)
UY (1) UY33455A (es)
WO (1) WO2011158870A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105579037A (zh) 2013-05-31 2016-05-11 武田制药美国有限公司 用黄嘌呤氧化酶抑制剂治疗的方法和含黄嘌呤氧化酶抑制剂的组合物
IL308650A (en) 2017-06-21 2024-01-01 Minerva Neurosciences Inc Stomach-resistant controlled-release oral dosage forms
JP7377782B2 (ja) * 2019-09-04 2023-11-10 信越化学工業株式会社 フィルム成形用組成物及びフィルム
JP7506475B2 (ja) * 2019-12-26 2024-06-26 東和薬品株式会社 フェブキソスタット製剤

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3720757A1 (de) 1987-06-24 1989-01-05 Bayer Ag Dhp-manteltablette
JP3220373B2 (ja) 1995-11-28 2001-10-22 バイエル薬品株式会社 持続性ニフエジピン製剤
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
ATE307803T1 (de) 1999-01-22 2005-11-15 Boehringer Ingelheim Pharma Herstellung von 3-amino-2-chlor-4-methylpyridin aus aceton und ethylcyanoacetat
AP1243A (en) 1999-02-01 2004-02-02 Servier Lab Core tablet for controlled release of gliclazide after oral administration.
EG23951A (en) 1999-03-25 2008-01-29 Otsuka Pharma Co Ltd Cilostazol preparation
JP4637338B2 (ja) 2000-09-22 2011-02-23 大塚製薬株式会社 シロスタゾール有核錠
JP4817562B2 (ja) * 2001-09-26 2011-11-16 東和薬品株式会社 長時間持続型ニフエジピン有核錠
JP5105684B2 (ja) * 2002-03-15 2012-12-26 大塚製薬株式会社 持続性医薬製剤
JP3751287B2 (ja) 2002-03-27 2006-03-01 バイエル薬品株式会社 小型化されたニフェジピン有核錠剤
JP4084309B2 (ja) * 2002-03-28 2008-04-30 帝人株式会社 単一の結晶形を含有する固形製剤
AU2003301121A1 (en) * 2002-12-18 2004-07-14 Pain Therapeutics, Inc. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
JP5059611B2 (ja) * 2005-08-18 2012-10-24 帝人ファーマ株式会社 正確な用量分割機能を有する製剤
PE20070698A1 (es) * 2005-11-14 2007-08-17 Teijin Pharma Ltd Comprimido de disgregacion rapida intraoral que contiene hidrocloruro de ambroxol
SG184754A1 (en) 2005-12-28 2012-10-30 Takeda Pharmaceutical Controlled release solid preparation
US20100172988A1 (en) 2006-01-10 2010-07-08 Kissei Pharmaceutical Co., Ltd. Sustained release preparation and method for production thereof
NZ580972A (en) * 2007-06-04 2012-02-24 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
WO2009028598A1 (ja) * 2007-08-31 2009-03-05 Daiichi Sankyo Company, Limited 徐放性製剤及びその製造方法
WO2009054550A1 (en) * 2007-10-25 2009-04-30 Bayer Yakuhin, Ltd. Nifedipine-containing press coated tablet and method of preparing the same
EP2446885B1 (en) * 2009-06-26 2017-09-06 Teijin Pharma Limited Therapeutic agent for hypertension or normal high blood pressure
CN101671315B (zh) * 2009-08-19 2011-06-22 何广卫 非布索坦的新晶型及其制备方法
CN101658505A (zh) 2009-09-29 2010-03-03 北京华禧联合科技发展有限公司 非布索坦的缓释制剂及其制备方法
JP5865904B2 (ja) * 2010-06-16 2016-02-17 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド キサンチンオキシドレダクターゼ阻害剤またはキサンチンオキシダーゼ阻害剤の新規の調節放出剤形

Also Published As

Publication number Publication date
JP5669837B2 (ja) 2015-02-18
WO2011158870A1 (ja) 2011-12-22
CA2802831C (en) 2018-11-20
US8968779B2 (en) 2015-03-03
JPWO2011158870A1 (ja) 2013-08-19
MX2012014437A (es) 2013-02-26
EP2594269A1 (en) 2013-05-22
EP2594269A4 (en) 2013-12-04
UY33455A (es) 2012-01-31
AR081935A1 (es) 2012-10-31
TW201206502A (en) 2012-02-16
US20130089609A1 (en) 2013-04-11
CA2802831A1 (en) 2011-12-22

Similar Documents

Publication Publication Date Title
IL253737A0 (en) Systems and methods for extracorporeal treatment of an organ and for the use of lactate as a sign of donor organ status
IL264441A (en) Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors
BR112013010078A2 (pt) sistema de prevenção de ferida de pressão e método para evitar o desenvolvimento de feridas de pressão de um indivíduo
WO2012068381A9 (en) Protection of renal tissues from schema through inhibition of the proliferative kisses cdk4 and cdk6
BR112012030561A2 (pt) sistema dealívio de tensão de implante de glossoplastia, método para indicar uma quanidade de força aplicada pela língua de um indivíduo a um sistema implantável e sistema implantável configurado para indicar uma quantidade de força aplicada pela língua de um indivíduo ao sistema implantável
EP3354640A3 (en) Mif inhibitors and their uses
EP2480914A4 (en) Systems and methods for the quantitative estimate of production-forecast uncertainty
EP2533825A4 (en) Cannula lined with tissue in-growth material and method of using the same
IL221412A0 (en) System and method for administering medicaments on the basis of urine values
WO2011039676A3 (en) Assessing patient compliance
EP2603176A4 (en) C1-C2 IMPLANT AND METHODS OF USE
EP2619194A4 (en) CATECHIN FATTY ACID DERIVATIVES AND METHODS OF USE
MX336777B (es) Peliculas y composiciones que comprenden las mismas.
IL221043A0 (en) Modified release formulation and methods of use
MX339452B (es) Tableta con nucleo recubierto de liberacion controlada.
IL255914B (en) A method that includes testing cells for the expression and/or secretion of one or more pro-angiogenic factors
PH12015502093A1 (en) Antiemetic extended release solid dosage forms
PH12016501756B1 (en) Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms
MX2014015488A (es) Nalmefeno para reducir el consumo de alcohol en poblaciones especificas.
IN2014DN07040A (es)
PT2384623E (pt) Composição em pó para a prevenção e tratamento de doenças dos cascos de animais
WO2011163539A3 (en) nAChRα7 AGONISTS AND nAChRα7 ANTAGONISTS FOR TREATING ULCERATIVE COLITIS (UC) AND CROHN'S DISEASE (CD)
SG10201403562UA (en) Implant for the treatment or prevention of an aneurysm
WO2009013885A1 (ja) Ｔ細胞のＴｈ１細胞への分化抑制剤
HU1000229D0 (en) Equipment for registering the excitement level as well as determining and recording the excitement condition of human beings

Legal Events

Date Code Title Description
FG Grant or registration